A note from the Editor: At The Grand Investor, we keep an eye out for favorable circumstances we believe will interest our readers. The following is one such message from one of our colleagues I think you’ll appreciate.
Early investors in Amgen earned as much as 46,751% returns.
And we believe early investors in this biotech have the potential to do the same.
Their patented CRISPR technology has the potential to edit DNA - "cutting" the harmful genes and "pasting" the healthy ones.
It's been called a "once-in-a-generation" opportunity.
And as a dominant player, this firm controls the CRISPR patent other companies must license.